Background At the end of 2018, South Africa updated its all-oral regimen, to include
bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9–12 …

In 2014, tuberculosis (TB) surpassed HIV as the leading infectious cause of death.
According to the World Health Organization (WHO), there were 10 million incident cases of …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

Purpose This study aimed to determine the prevalence and molecular characterization of
bedaquiline (BDQ) resistance among rifampicin-resistant tuberculosis (RR-TB) isolates …

Introduction Historically, extensively drug-resistant tuberculosis has been notoriously difficult
to treat with devasting outcomes. As we are coming to the end of an era where the 2006 …

About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen
lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis …

Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB
with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any …

Background Drug resistance threatens global tuberculosis control. We aimed to examine
mortality in patients with tuberculosis from high-burden countries, according to concordance …

Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and
millions of deaths each year. Around 10% of these cases are in children, but only a fraction …

Tuberculosis is the infectious disease that causes the most deaths each year in the world.
Around 25% of the population is estimated to be infected with, Mycobacterium tuberculosis …